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Abstract
PURPOSE: Pancreatic cancer still has one of the worst prognoses in gastrointestinal cancers with a 5-year survival
rate of 5%, making it necessary to find markers or gene sets that would further classify patients into different risk
categories and thus allow more individually adapted multimodality treatment regimens. In this study, we investi-
gated the prognostic values of HIF1a, bFGF, VEGF, and PDGFA gene expressions as well as their interrelation-
ships. EXPERIMENTAL DESIGN: Formalin-fixed paraffin-embedded tissue samples were obtained from 41 patients
with pancreatic adenocarcinoma (age, 65; range, 34–85 years). After laser capture microdissection, direct quanti-
tative real-time reverse transcription–polymerase chain reaction assays were performed in triplicates to determine
HIF1a, PDGFA, VEGF, and bFGF gene expression levels. Multivariate Cox proportional hazards regression analysis
was used to assess the impact of HIF1a gene expression on prognosis. RESULTS: HIF1a was significantly corre-
lated to every gene we tested: bFGF (P = .04), VEGF (P = .02), and PDGFA (P = .03). Tumor size, P = .04, and high
HIF1a mRNA expression (cutoff, 75th percentile) had a significant impact on survival, P = .009 (overall model fit,
P = .02). High HIF1a expression had a sensitivity of 87.1% and a specificity of 55.6% for the diagnosis short
(<6 months) versus long (6–60 months) survival. CONCLUSIONS: Measuring PDGFA, bFGF, and HIF1a expression
may contribute to a better understanding of the prognosis of patients with pancreatic cancer and may even play a
crucial role for the distribution of patients to multimodal therapeutic regimens. Larger studies including patients
treated with actual chemotherapeutics seem to be warranted.
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Introduction
Although rising for over 30 years, mortality rates of adenocarcinoma
of the pancreas in Europe have leveled off in the last 10 to 15 years
and have even decreased approximately 4% in the United States
[1,2]. Nonetheless, pancreatic cancer still has one of the worst prog-
noses in gastrointestinal cancers, with a 5-year survival rate of 5%.
Due to the late symptoms of pancreatic cancer and therefore often
late diagnosis, only 10% to 20% of the patients are eligible for com-
plete resection with curative intention, making it necessary to find
Abbreviations: HIF1a, hypoxia-inducible factor 1 alpha; PDGFA, platelet-derived
growth factor alpha; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast
growth factor; FFPE, formalin-fixed paraffin-embedded
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markers or gene sets that would further classify patients into differ-
ent risk categories and thus allow more individually adapted multi-
modality treatment regimens [3].
Several good candidate prognostic markers for pancreatic adeno-
carcinoma have been identified by previous work. Hypoxia-inducible
factor 1 alpha (HIF1a) has been shown to correlate with an unfavor-
able prognosis in many cancers and is known to regulate some genes
in the angiogenesis pathway [4]. Recently, Sun et al. [5] and Tao
et al. [6] showed with immunohistochemical methods that HIF1a
not only has a strong impact on the prognosis of patients with pan-
creatic ductal adenocarcinoma but is also correlated with vascular
endothelial growth factor (VEGF ) expression. Studies on human pan-
creatic cancer cells revealed that hypoxia and paracrine secretion of
insulin induced HIF1a expression, which in turn led to stimulated
glycolysis, cell proliferation, and VEGF secretion [7]. HIF1a binds
to the promoter region of VEGF and apparently thereby increases
the expression on VEGF under hypoxic conditions [8]. VEGF is
not only a key factor in the angiogenesis pathway but also a molecu-
lar drug target for several U.S. Food and Drug Administration–
approved chemotherapeutics [9]. Platelet-derived growth factor alpha
(PDGFA) has recently been discussed as a potential drug target in
pancreatic cancer [10]. It has to be further investigated in what re-
spect HIF1a and PDGFA are coexpressed in pancreatic cancer. The
expression of basic fibroblast growth factor (bFGF ) is known to have
a strong association with the prognosis of patients with pancreatic
cancer [11]. Some study groups showed a correlation between bFGF
and HIF1a expression in patients with breast and non–small cell lung
cancer [12,13]. However, this association is, like that of PDGFA and
HIF1a, little studied in pancreatic cancer.
In this study, we investigated the prognostic values of HIF1a,
bFGF, VEGF, and PDGFA gene expressions as well as their interrela-
tionships in pancreatic cancer. We measured the mRNA expression
levels of these genes with quantitative real-time reverse transcription–
polymerase chain reaction (RT-PCR) in formalin-fixed paraffin-
embedded (FFPE) tissue samples of pancreatic carcinoma. We then
further analyzed the previously mentioned genes and their correla-
tion with clinical and histopathologic variables such as tumor size
(diameter/volume), primary tumor stage [pT, based on the Interna-
tional Union Against Cancer (UICC), 1997], regional lymph node
metastasis, grading, and especially the survival time.
Materials and Methods
Study Population, Demographic Data, and Staging Procedures
Formalin-fixed paraffin-embedded samples were obtained from
41 patients with pancreatic adenocarcinoma with a median age of
65 years (range, 34–85 years) at the time of operation who were
scheduled for primary surgical resection. None of the patients had
received neoadjuvant or adjuvant radio-/chemotherapy. All patients
were treated at the University hospital of Cologne, North Rhine-
Westphalia, Germany, between December 1999 and July 2004.
Demographic, clinical, and histopathologic parameters are shown
in Table 1. Informed consent was obtained from each patient in accor-
dance with the requirements of our institution’s board of ethics. TNM
staging was performed according to the criteria of the UICC [14].
Microdissection
After a review of representative hematoxylin and eosin–stained
slides of the FFPE blocks by a pathologist to estimate the tumor load
per sample, section slides of 10-μm thickness were obtained for laser-
captured microdissection (P.A.L.M. Microlaser Technologies AG,
Munich, Germany). All tumor slides were prepared as described ex-
tensively by Vallbohmer et al. [15].
Isolation of RNA and cDNA Synthesis
The isolation of RNA from tumor tissue isolated by the micro-
dissection was performed in accordance with a patented proce-
dure at Response Genetics Inc (Los Angeles, CA; U.S. Patent No.
6248,535). The cDNA preparation steps were accomplished as de-
scribed previously [16].
Quantitative Real-Time Polymerase Chain Reaction
To quantify HIF1a, PDGFA, VEGF, and bFGF mRNA expres-
sion levels, we used an endogenous reference gene (β-actin) and
our gene set on a method based on real-time fluorescence detection
of amplified cDNA (ABI PRISM 7900 Sequence Detection System
[TaqMan]; Perkin-Elmer Applied Biosystems, Foster City, CA). The
RT-PCR was implemented as previously described by Kuramochi
et al. [17]. All genes were run on all samples in triplicates. The de-
tection of amplified cDNA results in a cycle threshold (C t) value that
is inversely proportional to the amount of cDNA. The higher the
ensuing C t value, the more PCR cycles were necessary to attain de-
tection limit, which means less cDNA. Colon, liver, and St. Universal
Mix RNA (Stratagene, La Jolla, CA) were used as control calibrators
on each plate. All primers were selected using the Gene Express soft-
ware (Applied Biosystems) but were adapted to the needs of RNA/
cDNA as extracted out of the paraffin-embedded tissue. All primers
were validated before use analogical to the described method of
Schneider et al. [18]. All results are expressed as ratios between two
absolute measurements (gene of interest/endogenous reference gene)
Table 1. Patient Characteristics (N = 41).
Parameter n (%)
Median age: 65 years (range, 34–85 years)
Sex
Male 23 (56.1)
Female 18 (43.9)
Histologic diagnosis
Adenocarcinoma 41 (100)
pT category
pT1 1 (2.4)
pT2 6 (14.6)
pT3 32 (78.0)
pT4 2 (4.9)
pN category
N − 7 (17.1)
N + 33 (80.5)
Not evaluated 1 (2.4)
c/pM category
c/pM0 41 (100)
Grading
G2 22 (53.7)
G3 19 (46.3)
Residual tumor category
R0 41 (100)
Tumor size (diameter; cm)
Minimum 1
Maximum 7
Range 6
UICC 1997 Tumor-Node-Metastasis (pTNM) Pathological Classification: pT indicates primary
tumor; pN, regional lymph node metastasis; c/pM, distant metastasis; G , grade of differentiation;
R, residual tumor category.
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to account for loading differences. We used a log transformation before
statistical analysis including a multiplier that accounts the average C t
values maintained for each gene during the validation process on the
calibrators and therefore allows comparing samples that were run on
different RT-PCR well plates.
Statistical Analysis
The correlation among gene expression levels, those and clinico-
pathologic parameters were tested with Spearman test for bivariate
correlations. Each gene was tested with the Kaplan–Meier method
to estimate overall survival and relapse-free survival. Differences in
survival between the high- and low-expression groups were analyzed
with the log rank test. To evaluate independent prognostic factors
associated with survival, multivariate Cox proportional hazards re-
gression analysis with stepwise selection was used, with the gene
set, tumor stage, tumor size (diameter/volume), and histologic char-
acteristics (grading) as covariates. A data mining technique provided
by the SAS Institute was used to split gene expression in high- and
low-level groups based on a platform that recursively partitions data
according to a relationship between the X and Y values, creating a
tree of partitions (recursive descent partition analysis). By searching
all possible cuts, it finds a set of cut points of X values (Gene Ex-
pression) that best predict the Y value (Survival Time). These data
splits are done, recursively forming a tree of decision rules until
the desired fit is reached; the most significant split is determined
by the largest likelihood ratio chi-square statistic. In either case,
the split is chosen to maximize the difference in the responses be-
tween the two branches of the split. This method was previously used
by Lu et al. [19]. We used receiver operating characteristic (ROC)
curve analysis to test the ability of the chosen cutoffs to discrimi-
nate short survivors (<6 months) from long survivors (6 months to
5 years). The level of significance was set to P < .05. All P values re-
ported were based on two-sided tests.
All statistical tests were performed using the Statistical Package for
the Social Sciences for Windows (Version 16.0; Chicago, IL) and the
JMP 7.0 Software (SAS, Cary, NC).
Results
The distribution of the log-transformed ΔC t values is shown in
Figure 1.
Spearman Test for Bivariate Correlations
Spearman test on the log-transformed ΔC t values showed signifi-
cant correlations between some of the gene expressions. HIF1a was
correlated to every gene we tested. HIF1a was significantly correlated
to bFGF at P = .04 (P < .05), it was associated to the VEGF gene
expression with a significance of P = .02 (P < .05) and to PDGFA
at a level of significance of P = .03 (P < .05). VEGF gene expression
and PDGFA expression levels were associated with a significance of
P = .02 (P < .05). We performed partition analysis of VEGF mRNA
expression based on the existence of lymph node metastasis, thereby
obtaining two groups with high versus low expression profiles. This
grouping showed a significant correlation to lymph node metasta-
sis with P = .04 (P < .05), thus implicating that a high expression
of VEGF is linked to a higher likelihood of lymph node metastasis.
Using the same method for the other used genes, no significant cor-
relation appeared. With a significance level of P = .01 (P < .05), a
high VEGF mRNA level was also connected to the size (in diameter)
of the resected pancreatic adenocarcinoma.
Figure 1. Scatterplot of the log-transformed ΔC t values for the studied genes. The lines represent the cutoff values based on recursive
descent partition analysis.
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Partition Tree Analysis of Genes Based on Survival Time
Using the survival (in days) as the factor to perform partition
analysis on the chosen gene set, bFGF showed up as the most signifi-
cant divisor (with the highest log rank). The next in line were first
HIF1a, then PDGFA, and then VEGF. The cutoff value for HIF1a
was 3.9 (the 75th percentile) leaving the high-expression group of
11 patients with a mean of 4.8 (range, 3.9–8.7) and the low-expression
group consisting of 30 patients with a mean of 3.2 (range, 0.6–3.8).
The groupings, respectively, the cutoffs for the other genes are indi-
cated in Figure 1.
Survival Analysis Using the Kaplan–Meier Method
The groupings obtained by the recursive descent partition analysis
were used for each gene to assign survival with Kaplan–Meier log rank
analysis. The level of significance for bFGF was P = .01 (Figure 2) and
for PDGFA, P = .003 (Figure 3). The P value of HIF1a only showed a
trend to significance.
Multivariate Cox Proportional Hazards Regression Analysis
We put all clinical and histopathologic parameters along with the
measured gene expressions in a stepwise multivariate Cox propor-
tional hazards regression model. The overall model fit had a signifi-
cance level of P = .02. There were two factors that had a significant
impact on the survival time in this patient cohort, namely, tumor
size, P = .04, and a high HIF1a mRNA expression (75th percentile
cutoff ), with a significance level of P = .009 (Figure 4).
Receiver Operating Characteristic
The 75th percentile cutoff of the HIF1a mRNA expression
showed a sensitivity (true-positive rate) of 87.1% and a specificity
(true-negative rate) of 55.6% for the diagnosis short (<6 months)
versus long (6 months to 5 years) survival. The area under the curve
was 0.713 (confidence interval, 0.549–0.845) with a significance
level of P = .043. The positive likelihood ratio (true-positive rate/
false-positive rate) was 1.96, and the negative likelihood ratio (false-
negative rate/true-negative rate) was 0.23.
Discussion
In this study, we determined the gene expressions of HIF1a,
VEGF, bFGF, and PDGFA in the FFPE samples of pancreatic can-
cer patients who did not receive any chemotherapy. By using laser
capture microdissection to isolate tumor tissue from the clinical spe-
cimens along with quantitative RT-PCR, we hoped to achieve a more
precise characterization of the associations of these gene expressions
with each other and with patients’ prognosis than was previously
available. By multivariate Cox regression analysis, HIF1a gene ex-
pression showed the most significant impact on prognosis in our pa-
tient cohort (P = .009).
It has to be mentioned that HIF1a is known to undergo a rapid
posttranscriptional degradation under normoxic conditions by the
Figure 2. Kaplan–Meier plot, estimating overall survival and relapse-
free survival. Differences in survival between the high and the low
bFGF expression groups were analyzed with the log rank test.
Figure 3. Kaplan–Meier plot, estimating overall survival and relapse-
free survival. Differences in survival between the high and the low
PDGFA expression groups were analyzed with the log rank test.
Figure 4. Survival plot from multivariate Cox regression analysis
estimating overall survival and relapse-free survival. The upper
light gray line represents the patients with a HIF1a expression of
lower than the 75th percentile.
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ubiquitin–proteasome system, which is restricted by an oxygen-
dependent degradation domain within HIF-1, but under hypoxic
conditions, the accumulation of HIF1a involves stabilization of the
protein [20]. For several genes, such as thymidylate synthase and di-
hydropyrimidine dehydrogenase, there have been studies that provided
information on a generally close linear correlation between the expres-
sion of mRNA and the protein expression [21,22]. Although the regu-
lation of HIF1a RNA expression seems to respond rapidly to the
oxygen concentrations in the cell [23], meaning that the mechanisms
of HIF1a regulation are transcriptional as well as posttranscriptional, it
is controversially discussed whether this mechanisms correlate well to
each other [24]. In this study, we show that the determination of quan-
titative levels of gene expressions may be valuable and important in
itself, regardless of whether it matches the protein or not. Although
there is posttranscriptional regulation of the HIF1a subunit, an ap-
proach to use mRNA expression for assessing the prognosis of patients
with pancreatic ductal adenocarcinoma seems to be feasible.
The results of this pilot study also show a strong correlation of
HIF1a to VEGF and underline the meaning of HIF1a for the angio-
genesis and its most prominent marker VEGF on pancreatic cancer.
Although we could not verify the results of Sun et al. [5] regarding
the meaning of VEGF for the survival of the patients, we were also
able to show that a high VEGF expression significantly correlated to
lymph node metastasis (P = .04) and tumor size (P = .01).
The heparin-binding bFGF is one of the more frequently de-
scribed genes in pancreatic cancer. The association of HIF1a and
bFGF has recently been shown in some cancers. Bos et al. [12] inves-
tigated 45 samples of invasive breast cancer with immunohistochem-
istry. They were able to show a significant association between HIF1a
and bFGF but could not show this for VEGF and HIF1a. Also, a
different member of the PDGF family than we studied had a signifi-
cant connection to HIF1a expression. Giatromanolaki et al. [13] ex-
amined 120 samples of patients with non–small cell lung cancer with
monoclonal antibodies on FFPE samples, assessing the relationship
between HIF1a, bFGF, VEGF, and PD-ECGF. In their patient co-
hort, the association between the expression of these proteins was
significant. A literature search disclosed no studies focusing on the
relationship between bFGF and HIF1a in pancreatic cancer. How-
ever, in our patient group, the association between these two genes
was significant, suggesting that the bFGF–HIF1a relationship also
has a role in pancreatic cancer, especially because of the impact on
prognosis both factors had. The survival probability was significantly
higher with P = .013 of patients with lower bFGF expression. As pre-
viously mentioned, the impact of HIF1a expression on prognosis was
the strongest genetic factor on our patient cohort and even stronger
than clinicopathologic parameters.
Although members of the PDGF family and their receptors have
recently been discussed as potential drug targets in cancer [10], little is
known about their role specifically in pancreatic cancer. As of today,
especially the connection between PDGFA and HIF1a, although de-
scribed in renal cell carcinoma, seems to be unevaluated in pancre-
atic cancer [25]. So far, the correlated mRNA expression of PDGFA
and VEGF in cancer has only been described in a few studies [26] but
not in pancreatic cancer tissue. In our patient samples, the correla-
tion between PDGFA and VEGF was significant at a level of P = .02.
The correlation between PDGFA and HIF1a was significant at P =
.03, and the survival probability of patients with a high PDGFA ex-
pression was significantly lower as of patients with a low expression of
the same gene (P = .003).
When using gene expression as an approach to classify tumors, one
can always question whether generally more aggressive tumors are
metabolically more active or whether the expression of certain genes
leads to a more aggressive tumor. Whereas this question cannot, of
course, be definitively answered from a correlative study, the fact that
these gene expressions did associate with various metrics of tumor
aggressiveness strengthens the hypothesis of cause, not effect. Identi-
fying genes that are associated with more aggressive tumors is useful
to form a candidate oncogene pool that is available for further work
to more definitively address the cause-or-effect question, such as
in vitro experiments where the genes in question are transfected into
cells. For example, insertion of a mutated p53 into cells has been
used to demonstrate that this gene directly causes many different ef-
fects, but it had to be identified first as being associated with more
aggressive tumors.
Conclusions
The significant impact of a high PDGFA expression on survival
probability (P = .003), the significantly higher survival probability
of patients with a low bFGF expression (P = .01), and the importance
of a high HIF1a expression (P = .009) in comparison to all clinico-
pathologic parameters suggest that these three genes may contribute
to a better understanding of the prognosis of patients with pancreatic
cancer and may even play a crucial role for the distribution of pa-
tients to multimodal therapeutic regimens. Larger studies including
patients treated with actual chemotherapeutics seem to be warranted.
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